Luye Pharma Conbercept

(Conbercept)

Phase 3Protein / enzyme

Conbercept is used to treat wet age-related macular degeneration, a disease that causes vision loss in older adults, and diabetic macular edema, which is swelling in the back of the eye caused by diabetes.[1] Luye Pharma Conbercept is currently being investigated across 3 indications[3], with its most advanced program in Phase 3.[1]

Luye Pharma Conbercept is one of 11 biologic programs targeting Retinopathy of Prematurity. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinopathy of PrematurityActive, not recruiting

Retinopathy of Prematurity (ROP)Recruiting

Non-Proliferative Diabetic RetinopathyActive, not recruiting

Retinopathy of PrematurityPreclinical

Active, not recruiting

Retinopathy of Prematurity (ROP)Preclinical

Recruiting

Non-Proliferative Diabetic RetinopathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Retinopathy of Prematurity

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

1 2

Advil

KKenvue Brands

Approved

1 3

Decadron

AAspen Global Incorporated

Approved

—4

Inderal

WWyeth-Lederle Vaccines

Phase 3

5 5

Luye Pharma Conbercept

CChengdu Kanghong Biotech Co., Ltd.

Phase 3

23 6

Paracetamol

GSK

Preclinical

2 7

Feosol

AAuerbach Hematology Oncology Associates P C

Preclinical

—8

Intravitreal Injection of Ranibizumab

UUniversity of Sao Paulo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Retinopathy of Prematurity (ROP)

NCT06717412

Clinical

Trials by Indication[1]

Diabetic Macular Edema3 trials

Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)

Unknown status·CChengdu Kanghong Biotech Co., Ltd.·Phase 3·NCT02194634·248 enrolled

Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE)

Unknown status·ZZhongshan Ophthalmic Center, Sun Yat-sen University·N/A·NCT04627402·50 enrolled

Evaluation of RC28-E Injection in Diabetic Macular Edema

Completed·RRemeGen Co., Ltd.·Phase 2·NCT04782115·156 enrolled

Retinal Vein Occlusion3 trials

Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion

Completed·CChengdu Kanghong Biotech Co., Ltd.·Phase 3·NCT03223714·242 enrolled

Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion

Completed·CChengdu Kanghong Biotech Co., Ltd.·Phase 3·NCT03108352·255 enrolled

Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion

Unknown status·CChengdu Kanghong Biotech Co., Ltd.·Phase 2·NCT01809236·60 enrolled

Treatment2 trials

Head to Head Study of Anti-VEGF Treatment.

Completed· Novartis logo

Novartis·Phase 4·NCT02577107·12 enrolled

Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma

Unknown status·SSun Yat-sen University·Phase 1·NCT03973125·50 enrolled

Choroidal Neovascularization2 trials

Intravitreal Conbercept for Idiopathic Choroidal Neovascularization

Unknown status·JJiao Mingfei·Phase 2·NCT02857517·50 enrolled

Conbercept in Choroidal Neovascularization Secondary to Uveitis

Unknown status·—·Phase 2·NCT02934841·40 enrolled

Polypoidal choroidal vasculopathy2 trials

Conbercept for Polypoidal Choroidal Vasculopathy（START Study）

Completed·PPeking Union Medical College Hospital··NCT05229237·500 enrolled

The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)

Unknown status·CChengdu Kanghong Biotech Co., Ltd.·Phase 4·NCT03159884·300 enrolled

11 more indications

Age-Related Macular Degeneration1 trial

Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration

Unknown status·XXiaodong Sun·Phase 4·NCT02802657·141 enrolled

Wet Age-Related Macular Degeneration1 trial

An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)

Unknown status·CChengdu Kanghong Biotech Co., Ltd.·Phase 2·NCT02098720·30 enrolled

Proliferative Diabetic Retinopathy1 trial

Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy

Completed·RRuijin Hospital·Phase 4·NCT02816710·112 enrolled

Vitrectomy1 trial

Intravitreal Conbercept After Vitrectomy

Completed·TTianjin Medical University Eye Hospital·Phase 1·NCT03426540·50 enrolled

Non-Proliferative Diabetic Retinopathy1 trial

Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy

Active, not recruiting·SShanghai Eye Disease Prevention and Treatment Center·Phase 4·NCT06305143·58 enrolled

TIA1 trial

Initial Versus Delayed PDT Combination With Conbercept in PCV

Completed·—·Phase 4·NCT02821520·80 enrolled

PRP1 trial

PRP vs PRP+IVC for Severe nPDR

Unknown status·RRuijin Hospital·N/A·NCT03863535·40 enrolled

Retinoblastoma1 trial

A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma

Unknown status·CChengdu Kanghong Biotech Co., Ltd.·Phase 2·NCT04990271·92 enrolled

Effectiveness1 trial

Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma

Unknown status·SSun Yat-sen University·Phase 1·NCT03571282·50 enrolled

Retinopathy of Prematurity (ROP)1 trial

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy: A Multicenter, Prospective, Randomized, Double-blind, Non-inferiority Clinical Trial

Recruiting·WWang Yusheng·Preclinical·NCT06717412·146 enrolled

Unspecified1 trial

Anti-VEGF in Real-world

Unknown status·WWenbin Wei··NCT05222633·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for Conbercept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Conbercept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Conbercept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chengdu Kanghong Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Vascular Endothelial Growth Factor B Inhibitor; Vascular Endothelial Growth Factor C Inhibitor; Placenta Growth Factor Inhibitor; Vascular Endothelial Growth Factor a Inhibitor[2]
Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: CChengdu Kanghong Biotech Co., Ltd.

Luye Pharma Conbercept

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Diabetic Macular Edema3 trials

Retinal Vein Occlusion3 trials

Treatment2 trials

Choroidal Neovascularization2 trials

Polypoidal choroidal vasculopathy2 trials

Age-Related Macular Degeneration1 trial

Wet Age-Related Macular Degeneration1 trial

Proliferative Diabetic Retinopathy1 trial

Vitrectomy1 trial

Non-Proliferative Diabetic Retinopathy1 trial

TIA1 trial

PRP1 trial

Retinoblastoma1 trial

Effectiveness1 trial

Retinopathy of Prematurity (ROP)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News